SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Growth in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 37,600 shares, an increase of 89.9% from the January 31st total of 19,800 shares. Based on an average daily volume of 69,500 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on SOPHiA GENETICS in a research note on Wednesday, December 18th. They set a “buy” rating and a $11.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP lifted its holdings in SOPHiA GENETICS by 23.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock valued at $68,000 after acquiring an additional 4,115 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $70,000. Green Alpha Advisors LLC lifted its holdings in SOPHiA GENETICS by 119.3% in the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after acquiring an additional 25,686 shares during the last quarter. Federated Hermes Inc. lifted its holdings in SOPHiA GENETICS by 40.5% in the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after acquiring an additional 28,819 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock valued at $2,180,000 after acquiring an additional 42,689 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Price Performance

Shares of SOPH stock traded up $0.07 during trading hours on Friday, reaching $3.67. The company had a trading volume of 27,120 shares, compared to its average volume of 99,662. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80. The stock has a fifty day moving average of $3.57 and a 200-day moving average of $3.56. The company has a market capitalization of $239.93 million, a price-to-earnings ratio of -3.37 and a beta of 1.03. SOPHiA GENETICS has a 12-month low of $2.70 and a 12-month high of $7.37.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.